Thierry Abribat
Director Ejecutivo en Millendo Therapeutics SAS .
Cargos activos de Thierry Abribat
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Director Ejecutivo | 08/09/2009 | - |
| Fundador | 08/09/2009 | - | |
| Presidente | 08/09/2009 | - | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Director/Miembro de la Junta | 30/07/2014 | - |
| Director Ejecutivo | 30/07/2014 | - | |
| Fundador | 30/07/2014 | - |
Historial de carrera de Thierry Abribat
Antiguos cargos conocidos de Thierry Abribat.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Director Ejecutivo | 01/01/2005 | 01/01/2007 |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Director/Miembro de la Junta | 20/12/2017 | - |
| THERATECHNOLOGIES INC. | Director Técnico/Científico/I+D | - | - |
| SANOFI | Director Técnico/Científico/I+D | - | - |
Formación de Thierry Abribat.
| Institut National Polytechnique de Toulouse | Doctorate Degree |
Estadísticas
Internacional
| Francia | 6 |
| Canadá | 2 |
| Estados Unidos | 2 |
Operativa
| Chief Executive Officer | 3 |
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectorial
| Health Technology | 7 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SANOFI | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Millendo Therapeutics SAS
Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France. | Health Technology |
EUSA Pharma SAS
EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Health Technology |
Amolyt Pharma SAS
Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
- Bolsa de valores
- Insiders
- Thierry Abribat
- Experiencia
